nodes	percent_of_prediction	percent_of_DWPC	metapath
Raltegravir—UGT1A1—Pazopanib—kidney cancer	0.263	0.436	CbGbCtD
Raltegravir—UGT1A1—Erlotinib—kidney cancer	0.188	0.311	CbGbCtD
Raltegravir—UGT1A1—Sorafenib—kidney cancer	0.153	0.253	CbGbCtD
Raltegravir—UGT1A1—urine—kidney cancer	0.0108	0.49	CbGeAlD
Raltegravir—CCR1—cortex of kidney—kidney cancer	0.00607	0.274	CbGeAlD
Raltegravir—UGT1A1—renal system—kidney cancer	0.00265	0.12	CbGeAlD
Raltegravir—UGT1A1—kidney—kidney cancer	0.00256	0.116	CbGeAlD
Raltegravir—UGT1A1—Porphyrin metabolism—ALAD—kidney cancer	0.00187	0.0793	CbGpPWpGaD
Raltegravir—UGT1A1—Codeine and Morphine Metabolism—ABCB1—kidney cancer	0.00126	0.0533	CbGpPWpGaD
Raltegravir—UGT1A1—Irinotecan Pathway—BCHE—kidney cancer	0.00107	0.0452	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—ANXA1—kidney cancer	0.000671	0.0284	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—OR4C13—kidney cancer	0.000655	0.0277	CbGpPWpGaD
Raltegravir—UGT1A1—Estrogen metabolism—GSTM1—kidney cancer	0.000639	0.027	CbGpPWpGaD
Raltegravir—UGT1A1—Estrogen metabolism—CYP1A1—kidney cancer	0.000606	0.0256	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—OR4C13—kidney cancer	0.000595	0.0252	CbGpPWpGaD
Raltegravir—UGT1A1—Irinotecan Pathway—APC—kidney cancer	0.00058	0.0246	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUND—kidney cancer	0.000574	0.0243	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—ANXA1—kidney cancer	0.000566	0.024	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—ACY1—kidney cancer	0.000512	0.0217	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—ANXA1—kidney cancer	0.00045	0.0191	CbGpPWpGaD
Raltegravir—UGT1A1—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	0.000415	0.0176	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUNB—kidney cancer	0.000391	0.0165	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—OR4C13—kidney cancer	0.000351	0.0149	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—ANXA1—kidney cancer	0.000343	0.0145	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—POMC—kidney cancer	0.000329	0.0139	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—SLC5A3—kidney cancer	0.000307	0.013	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—LATS1—kidney cancer	0.000299	0.0126	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CYP1A1—kidney cancer	0.000286	0.0121	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—GSTT1—kidney cancer	0.000282	0.0119	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—ALDH1A1—kidney cancer	0.000281	0.0119	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—POMC—kidney cancer	0.000277	0.0117	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—AKAP13—kidney cancer	0.000272	0.0115	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—KEAP1—kidney cancer	0.000268	0.0113	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—AMER1—kidney cancer	0.000254	0.0108	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—AKAP13—kidney cancer	0.000247	0.0105	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—ITPR2—kidney cancer	0.000231	0.00979	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—POMC—kidney cancer	0.000221	0.00934	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CER1—kidney cancer	0.000213	0.00901	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GPC3—kidney cancer	0.000213	0.00901	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—ITPR2—kidney cancer	0.00021	0.00889	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—GSTP1—kidney cancer	0.000195	0.00827	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—ANXA1—kidney cancer	0.000194	0.0082	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SFRP2—kidney cancer	0.000181	0.00766	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—GSTM1—kidney cancer	0.00018	0.0076	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—ANXA1—kidney cancer	0.000176	0.00745	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—POMC—kidney cancer	0.000168	0.00711	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTT1—kidney cancer	0.000165	0.00698	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—SLC5A5—kidney cancer	0.000162	0.00685	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—kidney cancer	0.000161	0.00682	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—kidney cancer	0.000158	0.00667	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—SLC2A1—kidney cancer	0.000156	0.00661	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—PTGS1—kidney cancer	0.000154	0.00654	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUN—kidney cancer	0.000153	0.00649	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CASP2—kidney cancer	0.000146	0.00617	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—AKAP13—kidney cancer	0.000146	0.00617	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—EGR1—kidney cancer	0.000145	0.00614	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GRB7—kidney cancer	0.000133	0.00565	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—GSTP1—kidney cancer	0.00013	0.00552	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ITPR2—kidney cancer	0.000124	0.00525	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—GSTM1—kidney cancer	0.00012	0.00507	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTP1—kidney cancer	0.000114	0.00484	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—GSTP1—kidney cancer	0.000113	0.00477	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CTNNA1—kidney cancer	0.000112	0.00476	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—EIF4EBP1—kidney cancer	0.000112	0.00473	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HSPB1—kidney cancer	0.000112	0.00473	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTM1—kidney cancer	0.000105	0.00445	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PSMD7—kidney cancer	0.000104	0.0044	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TSC1—kidney cancer	0.000104	0.0044	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ANXA1—kidney cancer	0.000104	0.0044	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—GSTM1—kidney cancer	0.000104	0.00438	CbGpPWpGaD
Raltegravir—Pain in extremity—Doxorubicin—kidney cancer	0.000103	0.000293	CcSEcCtD
Raltegravir—Paraesthesia—Gemcitabine—kidney cancer	0.000102	0.000292	CcSEcCtD
Raltegravir—Cardiac disorder—Capecitabine—kidney cancer	0.000102	0.000292	CcSEcCtD
Raltegravir—Cough—Paclitaxel—kidney cancer	0.000102	0.000291	CcSEcCtD
Raltegravir—Asthenia—Sunitinib—kidney cancer	0.000102	0.000291	CcSEcCtD
Raltegravir—Nausea—Vinblastine—kidney cancer	0.000101	0.000289	CcSEcCtD
Raltegravir—Somnolence—Gemcitabine—kidney cancer	0.000101	0.000289	CcSEcCtD
Raltegravir—Affect lability—Doxorubicin—kidney cancer	0.000101	0.000288	CcSEcCtD
Raltegravir—Migraine—Doxorubicin—kidney cancer	0.000101	0.000288	CcSEcCtD
Raltegravir—Nausea—Everolimus—kidney cancer	0.000101	0.000288	CcSEcCtD
Raltegravir—Diarrhoea—Sorafenib—kidney cancer	0.000101	0.000288	CcSEcCtD
Raltegravir—Hypertension—Paclitaxel—kidney cancer	0.000101	0.000288	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—FLT1—kidney cancer	0.000101	0.00426	CbGpPWpGaD
Raltegravir—Pruritus—Sunitinib—kidney cancer	0.0001	0.000287	CcSEcCtD
Raltegravir—Angiopathy—Capecitabine—kidney cancer	0.0001	0.000285	CcSEcCtD
Raltegravir—UGT1A1—Biological oxidations—CYP1A1—kidney cancer	9.96e-05	0.00421	CbGpPWpGaD
Raltegravir—Immune system disorder—Capecitabine—kidney cancer	9.95e-05	0.000284	CcSEcCtD
Raltegravir—Myalgia—Paclitaxel—kidney cancer	9.95e-05	0.000284	CcSEcCtD
Raltegravir—Chest pain—Paclitaxel—kidney cancer	9.95e-05	0.000284	CcSEcCtD
Raltegravir—Arthralgia—Paclitaxel—kidney cancer	9.95e-05	0.000284	CcSEcCtD
Raltegravir—Mediastinal disorder—Capecitabine—kidney cancer	9.93e-05	0.000283	CcSEcCtD
Raltegravir—Anxiety—Paclitaxel—kidney cancer	9.92e-05	0.000283	CcSEcCtD
Raltegravir—Face oedema—Doxorubicin—kidney cancer	9.91e-05	0.000283	CcSEcCtD
Raltegravir—Decreased appetite—Gemcitabine—kidney cancer	9.9e-05	0.000283	CcSEcCtD
Raltegravir—Hypersensitivity—Dactinomycin—kidney cancer	9.9e-05	0.000283	CcSEcCtD
Raltegravir—Chills—Capecitabine—kidney cancer	9.89e-05	0.000282	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	9.88e-05	0.000282	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Gemcitabine—kidney cancer	9.84e-05	0.000281	CcSEcCtD
Raltegravir—Discomfort—Paclitaxel—kidney cancer	9.83e-05	0.00028	CcSEcCtD
Raltegravir—Fatigue—Gemcitabine—kidney cancer	9.82e-05	0.00028	CcSEcCtD
Raltegravir—Gastrointestinal pain—Vincristine—kidney cancer	9.82e-05	0.00028	CcSEcCtD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP1A1—kidney cancer	9.82e-05	0.00416	CbGpPWpGaD
Raltegravir—Dizziness—Sorafenib—kidney cancer	9.76e-05	0.000278	CcSEcCtD
Raltegravir—Pain—Gemcitabine—kidney cancer	9.74e-05	0.000278	CcSEcCtD
Raltegravir—Constipation—Gemcitabine—kidney cancer	9.74e-05	0.000278	CcSEcCtD
Raltegravir—Nausea—Erlotinib—kidney cancer	9.74e-05	0.000278	CcSEcCtD
Raltegravir—Alopecia—Capecitabine—kidney cancer	9.74e-05	0.000278	CcSEcCtD
Raltegravir—Dry mouth—Paclitaxel—kidney cancer	9.73e-05	0.000278	CcSEcCtD
Raltegravir—Mood swings—Doxorubicin—kidney cancer	9.73e-05	0.000277	CcSEcCtD
Raltegravir—Diarrhoea—Sunitinib—kidney cancer	9.72e-05	0.000277	CcSEcCtD
Raltegravir—Mental disorder—Capecitabine—kidney cancer	9.65e-05	0.000275	CcSEcCtD
Raltegravir—Asthenia—Dactinomycin—kidney cancer	9.64e-05	0.000275	CcSEcCtD
Raltegravir—Confusional state—Paclitaxel—kidney cancer	9.62e-05	0.000274	CcSEcCtD
Raltegravir—Blood creatinine increased—Doxorubicin—kidney cancer	9.62e-05	0.000274	CcSEcCtD
Raltegravir—Malnutrition—Capecitabine—kidney cancer	9.59e-05	0.000274	CcSEcCtD
Raltegravir—Erythema—Capecitabine—kidney cancer	9.59e-05	0.000274	CcSEcCtD
Raltegravir—Body temperature increased—Vincristine—kidney cancer	9.49e-05	0.000271	CcSEcCtD
Raltegravir—Abdominal pain—Vincristine—kidney cancer	9.49e-05	0.000271	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—POMC—kidney cancer	9.49e-05	0.00402	CbGpPWpGaD
Raltegravir—Infection—Paclitaxel—kidney cancer	9.48e-05	0.00027	CcSEcCtD
Raltegravir—Flatulence—Capecitabine—kidney cancer	9.45e-05	0.00027	CcSEcCtD
Raltegravir—Dry skin—Doxorubicin—kidney cancer	9.41e-05	0.000268	CcSEcCtD
Raltegravir—Dysgeusia—Capecitabine—kidney cancer	9.39e-05	0.000268	CcSEcCtD
Raltegravir—Dizziness—Sunitinib—kidney cancer	9.39e-05	0.000268	CcSEcCtD
Raltegravir—Feeling abnormal—Gemcitabine—kidney cancer	9.39e-05	0.000268	CcSEcCtD
Raltegravir—Vomiting—Sorafenib—kidney cancer	9.38e-05	0.000268	CcSEcCtD
Raltegravir—Abdominal pain upper—Doxorubicin—kidney cancer	9.38e-05	0.000268	CcSEcCtD
Raltegravir—Nervous system disorder—Paclitaxel—kidney cancer	9.35e-05	0.000267	CcSEcCtD
Raltegravir—Thrombocytopenia—Paclitaxel—kidney cancer	9.34e-05	0.000266	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—JUNB—kidney cancer	9.33e-05	0.00395	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PAK1—kidney cancer	9.33e-05	0.00395	CbGpPWpGaD
Raltegravir—Rash—Sorafenib—kidney cancer	9.3e-05	0.000265	CcSEcCtD
Raltegravir—Dermatitis—Sorafenib—kidney cancer	9.3e-05	0.000265	CcSEcCtD
Raltegravir—Back pain—Capecitabine—kidney cancer	9.28e-05	0.000265	CcSEcCtD
Raltegravir—Breast disorder—Doxorubicin—kidney cancer	9.28e-05	0.000265	CcSEcCtD
Raltegravir—Skin disorder—Paclitaxel—kidney cancer	9.27e-05	0.000264	CcSEcCtD
Raltegravir—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	9.25e-05	0.000264	CcSEcCtD
Raltegravir—Headache—Sorafenib—kidney cancer	9.24e-05	0.000264	CcSEcCtD
Raltegravir—Hyperhidrosis—Paclitaxel—kidney cancer	9.22e-05	0.000263	CcSEcCtD
Raltegravir—Diarrhoea—Dactinomycin—kidney cancer	9.2e-05	0.000262	CcSEcCtD
Raltegravir—Nasopharyngitis—Doxorubicin—kidney cancer	9.18e-05	0.000262	CcSEcCtD
Raltegravir—Gastritis—Doxorubicin—kidney cancer	9.09e-05	0.000259	CcSEcCtD
Raltegravir—Alanine aminotransferase increased—Doxorubicin—kidney cancer	9.05e-05	0.000258	CcSEcCtD
Raltegravir—Vomiting—Sunitinib—kidney cancer	9.03e-05	0.000258	CcSEcCtD
Raltegravir—Body temperature increased—Gemcitabine—kidney cancer	9.01e-05	0.000257	CcSEcCtD
Raltegravir—Tremor—Capecitabine—kidney cancer	8.99e-05	0.000256	CcSEcCtD
Raltegravir—Rash—Sunitinib—kidney cancer	8.95e-05	0.000255	CcSEcCtD
Raltegravir—Dermatitis—Sunitinib—kidney cancer	8.94e-05	0.000255	CcSEcCtD
Raltegravir—Abdominal distension—Doxorubicin—kidney cancer	8.93e-05	0.000255	CcSEcCtD
Raltegravir—Ill-defined disorder—Capecitabine—kidney cancer	8.9e-05	0.000254	CcSEcCtD
Raltegravir—Headache—Sunitinib—kidney cancer	8.9e-05	0.000254	CcSEcCtD
Raltegravir—Influenza—Doxorubicin—kidney cancer	8.87e-05	0.000253	CcSEcCtD
Raltegravir—Anaemia—Capecitabine—kidney cancer	8.87e-05	0.000253	CcSEcCtD
Raltegravir—Hypersensitivity—Vincristine—kidney cancer	8.85e-05	0.000252	CcSEcCtD
Raltegravir—Eosinophilia—Doxorubicin—kidney cancer	8.79e-05	0.000251	CcSEcCtD
Raltegravir—Nausea—Sorafenib—kidney cancer	8.77e-05	0.00025	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—ACY1—kidney cancer	8.76e-05	0.00371	CbGpPWpGaD
Raltegravir—Musculoskeletal discomfort—Paclitaxel—kidney cancer	8.69e-05	0.000248	CcSEcCtD
Raltegravir—Malaise—Capecitabine—kidney cancer	8.65e-05	0.000247	CcSEcCtD
Raltegravir—Insomnia—Paclitaxel—kidney cancer	8.63e-05	0.000246	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—POMC—kidney cancer	8.62e-05	0.00365	CbGpPWpGaD
Raltegravir—Vertigo—Capecitabine—kidney cancer	8.62e-05	0.000246	CcSEcCtD
Raltegravir—Asthenia—Vincristine—kidney cancer	8.62e-05	0.000246	CcSEcCtD
Raltegravir—Paraesthesia—Paclitaxel—kidney cancer	8.57e-05	0.000244	CcSEcCtD
Raltegravir—Vomiting—Dactinomycin—kidney cancer	8.55e-05	0.000244	CcSEcCtD
Raltegravir—Bronchitis—Doxorubicin—kidney cancer	8.53e-05	0.000243	CcSEcCtD
Raltegravir—Somnolence—Paclitaxel—kidney cancer	8.48e-05	0.000242	CcSEcCtD
Raltegravir—Palpitations—Capecitabine—kidney cancer	8.48e-05	0.000242	CcSEcCtD
Raltegravir—Rash—Dactinomycin—kidney cancer	8.48e-05	0.000242	CcSEcCtD
Raltegravir—Nausea—Sunitinib—kidney cancer	8.43e-05	0.000241	CcSEcCtD
Raltegravir—Dyspepsia—Paclitaxel—kidney cancer	8.4e-05	0.00024	CcSEcCtD
Raltegravir—Cough—Capecitabine—kidney cancer	8.37e-05	0.000239	CcSEcCtD
Raltegravir—Neutropenia—Doxorubicin—kidney cancer	8.3e-05	0.000237	CcSEcCtD
Raltegravir—Decreased appetite—Paclitaxel—kidney cancer	8.29e-05	0.000237	CcSEcCtD
Raltegravir—Hypertension—Capecitabine—kidney cancer	8.28e-05	0.000236	CcSEcCtD
Raltegravir—Upper respiratory tract infection—Doxorubicin—kidney cancer	8.25e-05	0.000235	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Paclitaxel—kidney cancer	8.24e-05	0.000235	CcSEcCtD
Raltegravir—Fatigue—Paclitaxel—kidney cancer	8.22e-05	0.000235	CcSEcCtD
Raltegravir—Diarrhoea—Vincristine—kidney cancer	8.22e-05	0.000234	CcSEcCtD
Raltegravir—Asthenia—Gemcitabine—kidney cancer	8.17e-05	0.000233	CcSEcCtD
Raltegravir—Myalgia—Capecitabine—kidney cancer	8.17e-05	0.000233	CcSEcCtD
Raltegravir—Chest pain—Capecitabine—kidney cancer	8.17e-05	0.000233	CcSEcCtD
Raltegravir—Arthralgia—Capecitabine—kidney cancer	8.17e-05	0.000233	CcSEcCtD
Raltegravir—Constipation—Paclitaxel—kidney cancer	8.16e-05	0.000233	CcSEcCtD
Raltegravir—Pain—Paclitaxel—kidney cancer	8.16e-05	0.000233	CcSEcCtD
Raltegravir—Anxiety—Capecitabine—kidney cancer	8.14e-05	0.000232	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	8.11e-05	0.000231	CcSEcCtD
Raltegravir—Weight increased—Doxorubicin—kidney cancer	8.08e-05	0.00023	CcSEcCtD
Raltegravir—Discomfort—Capecitabine—kidney cancer	8.07e-05	0.00023	CcSEcCtD
Raltegravir—Pruritus—Gemcitabine—kidney cancer	8.06e-05	0.00023	CcSEcCtD
Raltegravir—Weight decreased—Doxorubicin—kidney cancer	8.03e-05	0.000229	CcSEcCtD
Raltegravir—Hyperglycaemia—Doxorubicin—kidney cancer	8e-05	0.000228	CcSEcCtD
Raltegravir—Dry mouth—Capecitabine—kidney cancer	7.99e-05	0.000228	CcSEcCtD
Raltegravir—Nausea—Dactinomycin—kidney cancer	7.98e-05	0.000228	CcSEcCtD
Raltegravir—Dizziness—Vincristine—kidney cancer	7.94e-05	0.000227	CcSEcCtD
Raltegravir—Infestation—Doxorubicin—kidney cancer	7.91e-05	0.000226	CcSEcCtD
Raltegravir—Infestation NOS—Doxorubicin—kidney cancer	7.91e-05	0.000226	CcSEcCtD
Raltegravir—Confusional state—Capecitabine—kidney cancer	7.89e-05	0.000225	CcSEcCtD
Raltegravir—Feeling abnormal—Paclitaxel—kidney cancer	7.86e-05	0.000224	CcSEcCtD
Raltegravir—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	7.84e-05	0.000224	CcSEcCtD
Raltegravir—Gastrointestinal pain—Paclitaxel—kidney cancer	7.8e-05	0.000223	CcSEcCtD
Raltegravir—Diarrhoea—Gemcitabine—kidney cancer	7.8e-05	0.000222	CcSEcCtD
Raltegravir—Renal failure—Doxorubicin—kidney cancer	7.78e-05	0.000222	CcSEcCtD
Raltegravir—Infection—Capecitabine—kidney cancer	7.78e-05	0.000222	CcSEcCtD
Raltegravir—Neuropathy peripheral—Doxorubicin—kidney cancer	7.76e-05	0.000221	CcSEcCtD
Raltegravir—Nervous system disorder—Capecitabine—kidney cancer	7.68e-05	0.000219	CcSEcCtD
Raltegravir—Thrombocytopenia—Capecitabine—kidney cancer	7.66e-05	0.000219	CcSEcCtD
Raltegravir—Vomiting—Vincristine—kidney cancer	7.64e-05	0.000218	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—IGF2—kidney cancer	7.63e-05	0.00323	CbGpPWpGaD
Raltegravir—Skin disorder—Capecitabine—kidney cancer	7.6e-05	0.000217	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CDKN2B—kidney cancer	7.6e-05	0.00322	CbGpPWpGaD
Raltegravir—Urticaria—Paclitaxel—kidney cancer	7.58e-05	0.000216	CcSEcCtD
Raltegravir—Rash—Vincristine—kidney cancer	7.57e-05	0.000216	CcSEcCtD
Raltegravir—Hyperhidrosis—Capecitabine—kidney cancer	7.57e-05	0.000216	CcSEcCtD
Raltegravir—Dermatitis—Vincristine—kidney cancer	7.57e-05	0.000216	CcSEcCtD
Raltegravir—Haematuria—Doxorubicin—kidney cancer	7.54e-05	0.000215	CcSEcCtD
Raltegravir—Abdominal pain—Paclitaxel—kidney cancer	7.54e-05	0.000215	CcSEcCtD
Raltegravir—Body temperature increased—Paclitaxel—kidney cancer	7.54e-05	0.000215	CcSEcCtD
Raltegravir—Headache—Vincristine—kidney cancer	7.52e-05	0.000215	CcSEcCtD
Raltegravir—Hepatobiliary disease—Doxorubicin—kidney cancer	7.48e-05	0.000213	CcSEcCtD
Raltegravir—Epistaxis—Doxorubicin—kidney cancer	7.46e-05	0.000213	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—PDHB—kidney cancer	7.45e-05	0.00315	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—POMC—kidney cancer	7.42e-05	0.00314	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—IGF1R—kidney cancer	7.38e-05	0.00312	CbGpPWpGaD
Raltegravir—Vomiting—Gemcitabine—kidney cancer	7.24e-05	0.000207	CcSEcCtD
Raltegravir—Rash—Gemcitabine—kidney cancer	7.18e-05	0.000205	CcSEcCtD
Raltegravir—Dermatitis—Gemcitabine—kidney cancer	7.18e-05	0.000205	CcSEcCtD
Raltegravir—Headache—Gemcitabine—kidney cancer	7.14e-05	0.000204	CcSEcCtD
Raltegravir—Nausea—Vincristine—kidney cancer	7.13e-05	0.000204	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Capecitabine—kidney cancer	7.13e-05	0.000203	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—RAF1—kidney cancer	7.11e-05	0.00301	CbGpPWpGaD
Raltegravir—Hepatitis—Doxorubicin—kidney cancer	7.1e-05	0.000203	CcSEcCtD
Raltegravir—Insomnia—Capecitabine—kidney cancer	7.08e-05	0.000202	CcSEcCtD
Raltegravir—Hypoaesthesia—Doxorubicin—kidney cancer	7.07e-05	0.000202	CcSEcCtD
Raltegravir—Paraesthesia—Capecitabine—kidney cancer	7.03e-05	0.000201	CcSEcCtD
Raltegravir—Hypersensitivity—Paclitaxel—kidney cancer	7.03e-05	0.0002	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—IL2—kidney cancer	7.02e-05	0.00297	CbGpPWpGaD
Raltegravir—Urinary tract disorder—Doxorubicin—kidney cancer	7.01e-05	0.0002	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—CCBL1—kidney cancer	7e-05	0.00296	CbGpPWpGaD
Raltegravir—Oedema peripheral—Doxorubicin—kidney cancer	7e-05	0.0002	CcSEcCtD
Raltegravir—Connective tissue disorder—Doxorubicin—kidney cancer	6.98e-05	0.000199	CcSEcCtD
Raltegravir—Urethral disorder—Doxorubicin—kidney cancer	6.96e-05	0.000199	CcSEcCtD
Raltegravir—Dyspepsia—Capecitabine—kidney cancer	6.89e-05	0.000197	CcSEcCtD
Raltegravir—Visual impairment—Doxorubicin—kidney cancer	6.84e-05	0.000195	CcSEcCtD
Raltegravir—Asthenia—Paclitaxel—kidney cancer	6.84e-05	0.000195	CcSEcCtD
Raltegravir—Decreased appetite—Capecitabine—kidney cancer	6.8e-05	0.000194	CcSEcCtD
Raltegravir—Nausea—Gemcitabine—kidney cancer	6.77e-05	0.000193	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Capecitabine—kidney cancer	6.76e-05	0.000193	CcSEcCtD
Raltegravir—Fatigue—Capecitabine—kidney cancer	6.75e-05	0.000193	CcSEcCtD
Raltegravir—Pruritus—Paclitaxel—kidney cancer	6.75e-05	0.000193	CcSEcCtD
Raltegravir—Erythema multiforme—Doxorubicin—kidney cancer	6.72e-05	0.000192	CcSEcCtD
Raltegravir—Pain—Capecitabine—kidney cancer	6.69e-05	0.000191	CcSEcCtD
Raltegravir—Constipation—Capecitabine—kidney cancer	6.69e-05	0.000191	CcSEcCtD
Raltegravir—Eye disorder—Doxorubicin—kidney cancer	6.64e-05	0.000189	CcSEcCtD
Raltegravir—Tinnitus—Doxorubicin—kidney cancer	6.62e-05	0.000189	CcSEcCtD
Raltegravir—Cardiac disorder—Doxorubicin—kidney cancer	6.59e-05	0.000188	CcSEcCtD
Raltegravir—Diarrhoea—Paclitaxel—kidney cancer	6.53e-05	0.000186	CcSEcCtD
Raltegravir—Feeling abnormal—Capecitabine—kidney cancer	6.45e-05	0.000184	CcSEcCtD
Raltegravir—Angiopathy—Doxorubicin—kidney cancer	6.44e-05	0.000184	CcSEcCtD
Raltegravir—Immune system disorder—Doxorubicin—kidney cancer	6.42e-05	0.000183	CcSEcCtD
Raltegravir—Gastrointestinal pain—Capecitabine—kidney cancer	6.4e-05	0.000183	CcSEcCtD
Raltegravir—Mediastinal disorder—Doxorubicin—kidney cancer	6.4e-05	0.000183	CcSEcCtD
Raltegravir—Chills—Doxorubicin—kidney cancer	6.37e-05	0.000182	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—IL2—kidney cancer	6.37e-05	0.0027	CbGpPWpGaD
Raltegravir—Dizziness—Paclitaxel—kidney cancer	6.31e-05	0.00018	CcSEcCtD
Raltegravir—Alopecia—Doxorubicin—kidney cancer	6.28e-05	0.000179	CcSEcCtD
Raltegravir—Mental disorder—Doxorubicin—kidney cancer	6.22e-05	0.000178	CcSEcCtD
Raltegravir—Urticaria—Capecitabine—kidney cancer	6.22e-05	0.000177	CcSEcCtD
Raltegravir—Body temperature increased—Capecitabine—kidney cancer	6.19e-05	0.000177	CcSEcCtD
Raltegravir—Abdominal pain—Capecitabine—kidney cancer	6.19e-05	0.000177	CcSEcCtD
Raltegravir—Erythema—Doxorubicin—kidney cancer	6.18e-05	0.000176	CcSEcCtD
Raltegravir—Malnutrition—Doxorubicin—kidney cancer	6.18e-05	0.000176	CcSEcCtD
Raltegravir—Flatulence—Doxorubicin—kidney cancer	6.09e-05	0.000174	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—HIF1A—kidney cancer	6.07e-05	0.00257	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GLIPR1—kidney cancer	6.07e-05	0.00257	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PPAT—kidney cancer	6.07e-05	0.00257	CbGpPWpGaD
Raltegravir—Vomiting—Paclitaxel—kidney cancer	6.07e-05	0.000173	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—TSC2—kidney cancer	6.06e-05	0.00256	CbGpPWpGaD
Raltegravir—Dysgeusia—Doxorubicin—kidney cancer	6.05e-05	0.000173	CcSEcCtD
Raltegravir—Rash—Paclitaxel—kidney cancer	6.01e-05	0.000172	CcSEcCtD
Raltegravir—Dermatitis—Paclitaxel—kidney cancer	6.01e-05	0.000171	CcSEcCtD
Raltegravir—Nervousness—Doxorubicin—kidney cancer	6.01e-05	0.000171	CcSEcCtD
Raltegravir—Back pain—Doxorubicin—kidney cancer	5.98e-05	0.000171	CcSEcCtD
Raltegravir—Headache—Paclitaxel—kidney cancer	5.98e-05	0.00017	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—KDR—kidney cancer	5.81e-05	0.00246	CbGpPWpGaD
Raltegravir—Hypersensitivity—Capecitabine—kidney cancer	5.77e-05	0.000165	CcSEcCtD
Raltegravir—Ill-defined disorder—Doxorubicin—kidney cancer	5.74e-05	0.000164	CcSEcCtD
Raltegravir—Anaemia—Doxorubicin—kidney cancer	5.71e-05	0.000163	CcSEcCtD
Raltegravir—Agitation—Doxorubicin—kidney cancer	5.68e-05	0.000162	CcSEcCtD
Raltegravir—Nausea—Paclitaxel—kidney cancer	5.67e-05	0.000162	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—FH—kidney cancer	5.64e-05	0.00239	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—APRT—kidney cancer	5.64e-05	0.00239	CbGpPWpGaD
Raltegravir—Asthenia—Capecitabine—kidney cancer	5.62e-05	0.00016	CcSEcCtD
Raltegravir—Malaise—Doxorubicin—kidney cancer	5.58e-05	0.000159	CcSEcCtD
Raltegravir—Vertigo—Doxorubicin—kidney cancer	5.55e-05	0.000158	CcSEcCtD
Raltegravir—Pruritus—Capecitabine—kidney cancer	5.54e-05	0.000158	CcSEcCtD
Raltegravir—Palpitations—Doxorubicin—kidney cancer	5.46e-05	0.000156	CcSEcCtD
Raltegravir—Cough—Doxorubicin—kidney cancer	5.4e-05	0.000154	CcSEcCtD
Raltegravir—Diarrhoea—Capecitabine—kidney cancer	5.36e-05	0.000153	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—APC—kidney cancer	5.35e-05	0.00226	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—KIT—kidney cancer	5.35e-05	0.00226	CbGpPWpGaD
Raltegravir—Hypertension—Doxorubicin—kidney cancer	5.34e-05	0.000152	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—GPC3—kidney cancer	5.31e-05	0.00225	CbGpPWpGaD
Raltegravir—Myalgia—Doxorubicin—kidney cancer	5.26e-05	0.00015	CcSEcCtD
Raltegravir—Chest pain—Doxorubicin—kidney cancer	5.26e-05	0.00015	CcSEcCtD
Raltegravir—Arthralgia—Doxorubicin—kidney cancer	5.26e-05	0.00015	CcSEcCtD
Raltegravir—Anxiety—Doxorubicin—kidney cancer	5.25e-05	0.00015	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	5.23e-05	0.000149	CcSEcCtD
Raltegravir—Discomfort—Doxorubicin—kidney cancer	5.2e-05	0.000148	CcSEcCtD
Raltegravir—Dizziness—Capecitabine—kidney cancer	5.18e-05	0.000148	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—CA2—kidney cancer	5.16e-05	0.00218	CbGpPWpGaD
Raltegravir—Dry mouth—Doxorubicin—kidney cancer	5.15e-05	0.000147	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—MAPK3—kidney cancer	5.12e-05	0.00217	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—POMC—kidney cancer	5.09e-05	0.00216	CbGpPWpGaD
Raltegravir—Confusional state—Doxorubicin—kidney cancer	5.09e-05	0.000145	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—ALAD—kidney cancer	5.03e-05	0.00213	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—BRAF—kidney cancer	5.03e-05	0.00213	CbGpPWpGaD
Raltegravir—Infection—Doxorubicin—kidney cancer	5.01e-05	0.000143	CcSEcCtD
Raltegravir—Vomiting—Capecitabine—kidney cancer	4.98e-05	0.000142	CcSEcCtD
Raltegravir—Nervous system disorder—Doxorubicin—kidney cancer	4.95e-05	0.000141	CcSEcCtD
Raltegravir—Thrombocytopenia—Doxorubicin—kidney cancer	4.94e-05	0.000141	CcSEcCtD
Raltegravir—Rash—Capecitabine—kidney cancer	4.94e-05	0.000141	CcSEcCtD
Raltegravir—Dermatitis—Capecitabine—kidney cancer	4.93e-05	0.000141	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—ST3GAL2—kidney cancer	4.91e-05	0.00208	CbGpPWpGaD
Raltegravir—Headache—Capecitabine—kidney cancer	4.9e-05	0.00014	CcSEcCtD
Raltegravir—Skin disorder—Doxorubicin—kidney cancer	4.9e-05	0.00014	CcSEcCtD
Raltegravir—Hyperhidrosis—Doxorubicin—kidney cancer	4.88e-05	0.000139	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—MAPK1—kidney cancer	4.87e-05	0.00206	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ALDH1A1—kidney cancer	4.8e-05	0.00203	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CA—kidney cancer	4.66e-05	0.00197	CbGpPWpGaD
Raltegravir—Nausea—Capecitabine—kidney cancer	4.65e-05	0.000133	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—KRAS—kidney cancer	4.6e-05	0.00195	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PGK1—kidney cancer	4.6e-05	0.00195	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SLC5A3—kidney cancer	4.6e-05	0.00195	CbGpPWpGaD
Raltegravir—Musculoskeletal discomfort—Doxorubicin—kidney cancer	4.6e-05	0.000131	CcSEcCtD
Raltegravir—Insomnia—Doxorubicin—kidney cancer	4.56e-05	0.00013	CcSEcCtD
Raltegravir—Paraesthesia—Doxorubicin—kidney cancer	4.53e-05	0.000129	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—LDHB—kidney cancer	4.51e-05	0.00191	CbGpPWpGaD
Raltegravir—Somnolence—Doxorubicin—kidney cancer	4.49e-05	0.000128	CcSEcCtD
Raltegravir—Dyspepsia—Doxorubicin—kidney cancer	4.44e-05	0.000127	CcSEcCtD
Raltegravir—Decreased appetite—Doxorubicin—kidney cancer	4.39e-05	0.000125	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Doxorubicin—kidney cancer	4.36e-05	0.000124	CcSEcCtD
Raltegravir—Fatigue—Doxorubicin—kidney cancer	4.35e-05	0.000124	CcSEcCtD
Raltegravir—Pain—Doxorubicin—kidney cancer	4.32e-05	0.000123	CcSEcCtD
Raltegravir—Constipation—Doxorubicin—kidney cancer	4.32e-05	0.000123	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—PIK3CA—kidney cancer	4.23e-05	0.00179	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—RAF1—kidney cancer	4.2e-05	0.00178	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—RELA—kidney cancer	4.18e-05	0.00177	CbGpPWpGaD
Raltegravir—Feeling abnormal—Doxorubicin—kidney cancer	4.16e-05	0.000119	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—ERBB2—kidney cancer	4.15e-05	0.00176	CbGpPWpGaD
Raltegravir—Gastrointestinal pain—Doxorubicin—kidney cancer	4.13e-05	0.000118	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MTOR—kidney cancer	4.1e-05	0.00174	CbGpPWpGaD
Raltegravir—Urticaria—Doxorubicin—kidney cancer	4.01e-05	0.000114	CcSEcCtD
Raltegravir—Abdominal pain—Doxorubicin—kidney cancer	3.99e-05	0.000114	CcSEcCtD
Raltegravir—Body temperature increased—Doxorubicin—kidney cancer	3.99e-05	0.000114	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—CA9—kidney cancer	3.91e-05	0.00166	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CDKN1B—kidney cancer	3.85e-05	0.00163	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—IL2—kidney cancer	3.76e-05	0.00159	CbGpPWpGaD
Raltegravir—Hypersensitivity—Doxorubicin—kidney cancer	3.72e-05	0.000106	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CCND1—kidney cancer	3.67e-05	0.00155	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—JUN—kidney cancer	3.66e-05	0.00155	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CTNNB1—kidney cancer	3.63e-05	0.00154	CbGpPWpGaD
Raltegravir—Asthenia—Doxorubicin—kidney cancer	3.62e-05	0.000103	CcSEcCtD
Raltegravir—Pruritus—Doxorubicin—kidney cancer	3.57e-05	0.000102	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—PTEN—kidney cancer	3.54e-05	0.0015	CbGpPWpGaD
Raltegravir—Diarrhoea—Doxorubicin—kidney cancer	3.45e-05	9.85e-05	CcSEcCtD
Raltegravir—Dizziness—Doxorubicin—kidney cancer	3.34e-05	9.52e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—CRABP1—kidney cancer	3.33e-05	0.00141	CbGpPWpGaD
Raltegravir—Vomiting—Doxorubicin—kidney cancer	3.21e-05	9.15e-05	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—VEGFA—kidney cancer	3.2e-05	0.00135	CbGpPWpGaD
Raltegravir—Rash—Doxorubicin—kidney cancer	3.18e-05	9.08e-05	CcSEcCtD
Raltegravir—Dermatitis—Doxorubicin—kidney cancer	3.18e-05	9.07e-05	CcSEcCtD
Raltegravir—Headache—Doxorubicin—kidney cancer	3.16e-05	9.02e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—ITPR2—kidney cancer	3.09e-05	0.00131	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MAPK3—kidney cancer	3.03e-05	0.00128	CbGpPWpGaD
Raltegravir—Nausea—Doxorubicin—kidney cancer	3e-05	8.55e-05	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MYC—kidney cancer	2.94e-05	0.00125	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MAPK1—kidney cancer	2.88e-05	0.00122	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTT1—kidney cancer	2.82e-05	0.00119	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ACHE—kidney cancer	2.82e-05	0.00119	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—KRAS—kidney cancer	2.72e-05	0.00115	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SCARB1—kidney cancer	2.67e-05	0.00113	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PTGS1—kidney cancer	2.64e-05	0.00112	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PSMD7—kidney cancer	2.59e-05	0.0011	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PIK3CA—kidney cancer	2.5e-05	0.00106	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—BCHE—kidney cancer	2.46e-05	0.00104	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SLC5A5—kidney cancer	2.43e-05	0.00103	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TP53—kidney cancer	2.42e-05	0.00102	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SLC2A1—kidney cancer	2.34e-05	0.000992	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTP1—kidney cancer	1.95e-05	0.000827	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ABCB1—kidney cancer	1.85e-05	0.000783	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTM1—kidney cancer	1.8e-05	0.00076	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CYP1A1—kidney cancer	1.7e-05	0.000721	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—POMC—kidney cancer	1.27e-05	0.000537	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PTGS2—kidney cancer	1.01e-05	0.000429	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PTEN—kidney cancer	8.83e-06	0.000374	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CA—kidney cancer	6.23e-06	0.000264	CbGpPWpGaD
